APA (7th ed.) Citation

E, S., MR, S., E, G., J, P., I, Ł., A, S., . . . G, M. (2026). Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion. Cancer, 132(15), e70544. https://doi.org/10.1002/cncr.70544

Chicago Style (17th ed.) Citation

E, Shenderov, et al. "Vobramitamab Duocarmazine, an Anti-B7-H3 Antibody-drug Conjugate, in Patients with Advanced Solid Tumors: Final Results of a Phase 1 Cohort Expansion." Cancer 132, no. 15 (2026): e70544. https://doi.org/10.1002/cncr.70544.

MLA (9th ed.) Citation

E, Shenderov, et al. "Vobramitamab Duocarmazine, an Anti-B7-H3 Antibody-drug Conjugate, in Patients with Advanced Solid Tumors: Final Results of a Phase 1 Cohort Expansion." Cancer, vol. 132, no. 15, 2026, p. e70544, https://doi.org/10.1002/cncr.70544.